More good news for ALK-Abelló's pollen allergy vaccine Grazax  

2006.12.28
A clinical study of Grazax, Danish pharmaceutical company ALK-Abelló's new tablet-based vaccine for the treatment of pollen allergy, shows improved effect in the second treatment season
A clinical study of Grazax, Danish pharmaceutical company ALK-Abelló's new tablet-based vaccine for the treatment of pollen allergy, shows improved effect in the second treatment season, supporting expectations of a lasting effect after the recommended three year treatment period ends. Such a lasting effect cannot reportedly be obtained with traditional symptom-relieving allergy medication.
 
Professor G. Walter Canonica of the University of Genova, Italy, and one of the world's leading allergy specialists says: "These new clinical results are very positive and add important new information to our understanding of tablet-based allergy vaccination."
 
Grazax is a self-administered once-daily tablet which targets the underlying cause of hay fever – the allergy itself – rather than just ameliorating the symptoms. It could thus provide a practical means to greatly increase the number of patients who can benefit from allergen specific immunotherapy, which WHO regards as the only treatment with the potential to actually cure the allergy, because it addresses the root cause. At least 45 million people are estimated to suffer from grass pollen allergy in the shape of allergic rhinitis (hay fever) or allergic asthma – or both.
 
Headquartered in Hørsholm north of Copenhagen, ALK-Abelló is a Stock Exchange listed company which has been active in allergy immunotherapy since 1923. The company's product pipeline contains tablet-based treatments, based on natural allergens, against grass and house dust mites. Alk-Abelló employs more than 1,300 people and has subsidiaries, production facilities and distributors throughout the world.
 
Link > ALK-Abelló   

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×